

This communication should be viewed by:

- Primary Care Providers
- Behavioral Health Providers
- Clinical staff
- Specialists

Pharmaceutical Policy Updates

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The following policies will be available for viewing on or before November 1, 2025. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status	Pharmaceutical Policy Name	Status
Effective October 1, 2025		Effective December 1, 2025	
Prademagene Zamikeracel (Zevaskyn)	New	Entyvio	Updated
Palivizumab	Updated	Entyvio Part B	Updated
		Etrasimod	Reviewed/No Changes
Effective November 1, 2025		Resmetirom	Updated
Agents for Fabry Disease	New	Risankizumab (Skyrizi)	Reviewed/No Changes
Anifrolumab	New	Risankizumab (Skyrizi) Part B	Reviewed/No Changes
Belimumab	New	Secukinumab (Cosentyx)	Updated
Crinecerfont	New	Secukinumab Part B	Reviewed/No Changes
Eladocagene Exuparvovec (Kebilidi)	New	Effective January 1, 2026	
Lebrikizumab (Ebglyss)	New	Hetlioz (tasimelteon)	New
Niktimvo	New	Pharmacy Management Programs External	Reviewed/No Changes
Tryngolza	New	Step therapy Policy	New
		Ustekinumab	Updated
		Ustekinumab Part B	Updated
		Weight Loss Medications	Updated

A note on Synagis (Palivizumab):

On September 5, 2025, Sobi, the manufacturer of Synagis, announced they are voluntarily discontinuing the availability of Synagis for RSV prophylaxis on December 31, 2025. On December 31, 2025, Synagis will no longer be manufactured, distributed or available for purchase. This applies to all settings of care and all patient populations. Due to the inability to complete the full five-dose regimen or required regimen beyond December 31, 2025, Synagis is excluded from coverage for the 2025-2026 RSV season.

Beyfortus and Enflonsia are available without prior authorization for RSV prevention.